Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Ovarian Res. 2019 Jul 25;12(1):69. doi: 10.1186/s13048-019-0543-z.
There is no consensus on the optimal chemotherapy regimen and the prognostic factors for ovarian large cell neuroendocrine carcinoma (LCNEC), a rare type of tumor. The objective of the present study is to present the case of a recent encounter of pure ovarian LCNEC and perform a brief review to summarize the clinicopathological features and prognostic factors of 57 cases of LCNEC patients that have been previously reported.
CASE PRESENTATION: Eligible studies were searched for online and 57 cases with clear follow-up data were found to have been reported. We present the 58th case, which is of a 70-year-old woman with stage IIIc primary pure LCNEC of the ovary. The initial symptom of this patient was abdominal distension (more than 2 months). A recent ultrasound test showed a solid-cystic mass occupying the pelvic and abdominal cavity. She received two courses of cisplatin-etoposide chemotherapy as an adjuvant therapy. No signs of nonclinical or radiological evidence of disease recurrence was found at follow-up examinations during the first 3 months after operation. A retrospective review of these 58 cases was conducted and survival curves were estimated. Using the Kaplan-Meier method.
The patients included were aged between 18 and 80 years. A Kaplan-Meier survival curve revealed that the median overall survival was 10.000 months, while 26 (44.83%) patients died within 12 months. We compared the overall mean survival time of all patients with that of stage I patients (42.418 vs 42.047 months), which suggests that ovarian LCNEC has a very poor prognosis even at stage I. Mean survival was longer for patients who had undergone postoperative chemotherapy than for those without postoperative chemotherapy (48.082 vs 9.778 months). A small series, such as this, does not provide adequate data to establish a firm correlation between the postoperative chemotherapy and prognosis (p = 0.176). In our review of 58 cases with ovarian LCNEC, prognosis was unfavorable in most cases. Given the rarity of LCNEC, it is highly recommended that a global medical database of ovarian LCNEC and a standard system of diagnosis and treatment is established.
卵巢大细胞神经内分泌癌(LCNEC)是一种罕见的肿瘤,目前对于其最佳化疗方案和预后因素尚无共识。本研究旨在报道一例近期发现的纯卵巢 LCNEC 病例,并对 57 例 LCNEC 患者的临床病理特征和预后因素进行简要综述。
病例介绍:在线搜索符合条件的研究,发现 57 例具有明确随访数据的病例已被报道。我们报告第 58 例病例,为一名 70 岁女性,患有 IIIc 期原发性卵巢单纯 LCNEC。该患者的初始症状为腹胀(超过 2 个月)。最近的超声检查显示盆腔和腹腔内有实性囊性肿块。她接受了两个疗程顺铂-依托泊苷化疗作为辅助治疗。术后 3 个月的随访检查未发现非临床或影像学疾病复发迹象。对这 58 例病例进行回顾性分析,并绘制生存曲线。采用 Kaplan-Meier 法。
纳入的患者年龄在 18 至 80 岁之间。Kaplan-Meier 生存曲线显示中位总生存期为 10.000 个月,26(44.83%)例患者在 12 个月内死亡。我们比较了所有患者的总体平均生存时间与 I 期患者的平均生存时间(42.418 与 42.047 个月),这表明即使在 I 期,卵巢 LCNEC 的预后也非常差。术后接受化疗的患者平均生存时间长于未接受化疗的患者(48.082 与 9.778 个月)。这样的小系列研究并不能提供足够的数据来确定术后化疗与预后之间的牢固相关性(p=0.176)。在我们对 58 例卵巢 LCNEC 病例的回顾中,大多数病例的预后均不佳。鉴于 LCNEC 的罕见性,强烈建议建立全球卵巢 LCNEC 医学数据库和诊断治疗标准系统。